EC Neurology

Review Article Volume 16 Issue 11 - 2024

Genetic Addiction Risk Severity (GARS) Test in Addiction Medicine: Early Identification of Pre-Addiction Phenotype

Kenneth Blum1-5,8*, Margaret A Madigan3, Panayotis K Thanos1,7, Kai-Uwe Lewandrowski8-10, Alireza Sharafshah11, Igor Elman1,12, David Baron2,13, Abdalla Bowirrat1, Albert Pinhasov1, Keerthy Sunder14, Shaurya Mahajan3, Milan T Makale15, Kevin Murphy16, Eric R Braverman3 and Rajendra D Badgaiyan17

1Department of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel

2Division of Addiction Research and Education, Center for Sports, Exercise, and Mental Health, Western University of Health Sciences, Pomona, CA., USA

3Division of Clinical Neurology, The Kenneth Blum Institute of Neurogenetics and Behavior, LLC, Austin, TX, USA

4Department of Psychiatry, University of Vermont School of Medicine, Burlington, VA, USA

5Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary

6Department of Psychiatry, Wright University Boonshoff School of Medicine, Dayton, OH, USA

7Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biosciences, Clinical Research Institute on Addictions, State University of New York at Buffalo, Buffalo, NY, USA

8Division of Personalized Pain Therapy Research, Center for Advanced Spine Care of Southern Arizona, Tucson, AZ, USA

9Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá D.C., Colombia

10Department of Orthopedics at Hospital Universitário Gaffree Guinle Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

11Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

12Department of Psychiatry, Harvard University College of Medicine, Cambridge, MA, USA

13Department of Psychiatry, Stanford University School of Medicine, Palo Alto, CA, USA

14Department of Medicine, University of California, Riverside School of Medicine, Riverside, CA, USA

15Department of Radiation Oncology, University of California San Diego, La Jolla, CA, USA

16Division of Personalized Neuromodulation, PeakLogic, LLC., Del Mar, CA, USA

17Department of Psychiatry, Texas Tech University Health Sciences School of Medicine, Lubbock, Tx, USA

*Corresponding Author:Kenneth Blum, Division of Addiction Research and Education, Center for Sports, Exercise, and Mental Health, Western University of Health Sciences, Pomona, CA, USA.
Received: September 23, 2024; Published: October 22, 2024



This expert opinion will detail the gene addiction connection: gene alleles and genetic testing. The Neurogeneticist Kenneth Blum, with Ernest Noble, published the first study to associate an allele of the Dopamine D2 Receptor Gene (DRD2) and severe alcoholism in JAMA 1990. This research confirmed an association preempted by a theoretical construct that identified the neurotransmitter interaction leading to dopamine release in the mesolimbic system as the “Brain Reward Cascade” in 1989. Earlier basic research had identified the role endorphins played in alcoholism, the blocking effect of Naloxone, an opioid-receptor antagonist in alcohol dependence, and supported the concept of a common mechanism between alcohol and opiates. Blum., et al. also developed a theory based on binding studies and other basic research that identified a “hypodopaminergic” trait/state caused by either genetics, stress, or toxicity as “Reward Deficiency Syndrome” (RDS). Blum’s group developed a nutraceutical therapy (scientific code) KB220Z to treat RDS and the Addiction Risk Severity (GARS) test to identify genetic risk for RDS. Reward deficiency syndrome, characterized as a relative failure of the neurotransmitter system in brain reward mechanisms, has been linked to dopaminergic dysfunction, acute excess, or chronic deficit of dopamine release in the brain reward circuitry. The reward deficiency behaviors include drug and non-drug addictive, compulsive, and impulsive behaviors.

 Keywords: Genetic Addiction Risk Severity (GARS); Addiction Medicine; Pre-Addiction Phenotype

  1. McCoy AN and Tan SY. “Otto Loewi (1873-1961): Dreamer and Nobel laureate”. Singapore Medical Journal 1 (2014): 3-4.
  2. Nicholls M. “Sir Bernard Katz: Sir Bernard Katz was jointly awarded the 1970 Nobel Prize for Physiology or Medicine with Ulf von Euler and Julius Axelrod for discoveries concerning ‘the humoral transmitters in the nerve terminals and the mechanisms for their storage, release, and inactivation’”. European Heart Journal22 (2020): 2045-2047.
  3. Yeragani VK., et al. “Arvid Carlsson, and the story of dopamine”. Indian Journal of Psychiatry 1 (2010): 87-88.
  4. Teleanu RI., et al. “Neurotransmitters-key factors in neurological and neurodegenerative disorders of the central nervous system”. International Journal of Molecular Sciences 11 (2022): 5954.
  5. Changeux JP. “The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily”. Journal of Biological Chemistry 48 (2012): 40207-40215.
  6. Trachtenberg MC and Blum K. “Alcohol and opioid peptides: neuropharmacological rationale for physical craving of alcohol”. American Journal of Drug and Alcohol Abuse 3 (1987): 365-372.
  7. Blum K., et al. “Ethanol acceptance as a function of genotype amounts of brain [Met]enkephalin”. Proceedings of the National Academy of Sciences of the United States of America 21 (1983): 6510-6512.
  8. Blum K and GP K. “Ethanol and neuromodulator interaction: a cascade model of reward”. Ollat H, Parvez S, Parvez H, editors. The Netherlands: VSP Press Utrecht (1990).
  9. Wise RA and Bozarth MA. “Brain reward circuitry: four circuit elements "wired" in apparent series”. Brain Research Bulletin 2 (1984): 203-208.
  10. Wise RA and Bozarth MA. “Brain mechanisms of drug reward and euphoria”. Psychiatry and Medicine 4 (1985): 445-460.
  11. Kotyuk E., et al. “Co-occurrences of substance use and other potentially addictive behaviors: Epidemiological results from the Psychological and Genetic Factors of the Addictive Behaviors (PGA) Study”. Journal of Behavioral Addictions 2 (2020): 272-288.
  12. Berridge KC and Robinson TE. “Liking, wanting, and the incentive-sensitization theory of addiction”. American Psychologist 8 (2016): 670-679.
  13. Blum K., et al. “"Liking" and "wanting" linked to Reward Deficiency Syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry”. Current Pharmaceutical Design 1 (2012): 113-118.
  14. File D., et al. “The role of impulsivity and reward deficiency in "liking" and "wanting" of potentially problematic behaviors and substance uses”. Frontiers in Psychiatry 13 (2022): 820836.
  15. Norman TR and Olver JS. “A challenge to the dopamine orthodoxy in schizophrenia?” Australian and New Zealand Journal of Psychiatry 9 (2023): 1198-1199.
  16. Gold MS., et al. “Molecular role of dopamine in anhedonia linked to reward deficiency syndrome (RDS) and anti- reward systems”. Frontiers in Bioscience (Scholar Edition)2 (2018): 309-325.
  17. Lewis RG., et al. “The Brain's Reward System in Health and Disease”. Advances in Experimental Medicine and Biology 1344 (2021): 57-69.
  18. Berridge KC and Kringelbach ML. “Building a neuroscience of pleasure and well-being”. Psychological Well-Being 1 (2011): 1-3.
  19. Friedman NP and Robbins TW. “The role of prefrontal cortex in cognitive control and executive function”. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology1 (2022): 72-89.
  20. Blum K., et al. “Dopaminergic dysfunction: Role for genetic and epigenetic testing in the new psychiatry”. Journal of the Neurological Sciences 453 (2023): 120809.
  21. Valenzuela CF., et al. “Focus on: neurotransmitter systems”. Alcohol Research and Health 1 (2011): 106-120.
  22. Noble EP., et al. “Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism”. Archives of General Psychiatry 7 (1991): 648-654.
  23. Alvarez-Bagnarol Y., et al. “Inhibition of dorsal raphe GABAergic neurons blocks hyperalgesia during heroin withdrawal”. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology9 (2023): 1300-1308.
  24. Madigan MA., et al. “Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?” International Journal of Environmental Research and Public Health 11 (2022): 6395.
  25. Blum K., et al. “Offering a putative neurobiological "dopamine homeostatic" solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of "precision behavioral management"”. Annals of Translational Medicine 23 (2022): 1291.
  26. Badgaiyan RD., et al. “Attenuated Tonic and Enhanced Phasic Release of Dopamine in Attention Deficit Hyperactivity Disorder”. PLoS One9 (2015): e0137326.
  27. Blum K., et al. “Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions”. International Journal of Environmental Research and Public Health 21 (2021): 11529.
  28. Blum K., et al. “Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors”. Journal of Psychoactive Drugs i-iv (2000): 1-112.
  29. Blum K., et al. “The D2 dopamine receptor gene as a determinant of reward deficiency syndrome”. Journal of the Royal Society of Medicine 7 (1996): 396-400.
  30. Robinson TE and Berridge KC. “The neural basis of drug craving: An incentive-sensitization theory of addiction”. Brain Research Reviews3 (1993): 247-291.
  31. Koob GF and Volkow ND. “Neurobiology of addiction: a neurocircuitry analysis”. Lancet Psychiatry8 (2016): 760-73.
  32. Volkow ND., et al. “Dopamine in drug abuse and addiction: results of imaging studies and treatment implications”. Archives of Neurology11 (2007): 1575-1579.
  33. Thanos PK., et al. “Daily treadmill exercise attenuates cocaine cue-induced reinstatement and cocaine induced locomotor response but increases cocaine-primed reinstatement”. Behavioural Brain Research 239 (2013): 8-14.
  34. Thanos PK., et al. “Dopamine D2R DNA transfer in dopamine D2 receptor-deficient mice: effects on ethanol drinking”. Life Sciences 2 (2005): 130-139.
  35. Volkow ND., et al. “Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity”. Proceedings of the National Academy of Sciences of the United States of America 30 (2014): E3149-E3156.
  36. Blum K., et al. “rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts”. Postgraduate Medicine 2 (2015): 232-241.
  37. Gyollai A., et al. “The genetics of problem and pathological gambling: a systematic review”. Current Pharmaceutical Design 25 (2014): 3993-3999.
  38. Cocker PJ., et al. “Irrational choice under uncertainty correlates with lower striatal D(2/3) receptor binding in rats”. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience44 (2012): 15450-15457.
  39. Petry NM., et al. “Behavioral Addictions as Mental Disorders: To Be or Not To Be?” Annual Review of Clinical Psychology 14 (2018): 399-423.
  40. Onnink AM., et al. “Enlarged striatal volume in adults with ADHD carrying the 9-6 haplotype of the dopamine transporter gene DAT1”. Journal of Neural Transmission (Vienna, Austria: 1996)8 (2016): 905-915.
  41. Bannon MJ., et al. “The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders”. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology6 (2001): 449-455.
  42. VanNess SH., et al. “The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density”. BMC Genetics 6 (2005): 55.
  43. Spencer TJ., et al. “Functional genomics of attention-deficit/hyperactivity disorder (ADHD) risk alleles on dopamine transporter binding in ADHD and healthy control subjects”. Biological Psychiatry 2 (2013): 84-89.
  44. Bowirrat A., et al. “Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability”. Current Neuropharmacology 4 (2010): 335-358.
  45. O'Doherty DCM., et al. “Frontal and subcortical grey matter reductions in PTSD”. Psychiatry Research Neuroimaging 266 (2017): 1-9.
  46. van Wingen GA., et al. “Persistent and reversible consequences of combat stress on the mesofrontal circuit and cognition”. Proceedings of the National Academy of Sciences of the United States of America 38 (2012): 15508-15513.
  47. Koob GF and Le Moal M. “Plasticity of reward neurocircuitry and the 'dark side' of drug addiction”. Nature Neuroscience 11 (2005): 1442-1444.
  48. Krupitsky E., et al. “Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial”. Lancet9776 (2011): 1506-1513.
  49. Lee JD., et al. “Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders”. New England Journal of Medicine 13 (2016): 1232-1242.
  50. Watts BV., et al. “Association of medication treatment for opioid use disorder with suicide mortality”. The American Journal of Psychiatry4 (2022): 298-304.
  51. van Hell HH., et al. “Involvement of the endocannabinoid system in reward processing in the human brain”. Psychopharmacology (Berl)4 (2012): 981-990.
  52. Yuan S., et al. “Neural effects of cognitive behavioral therapy in psychiatric disorders: a systematic review and activation likelihood estimation meta-analysis”. Frontiers in Psychology 13 (2022): 853804.
  53. McKay D., et al. “Efficacy of cognitive-behavioral therapy for obsessive-compulsive disorder”. Psychiatry Research3 (2015): 236-246.
  54. Diefenbach GJ., et al. “Repetitive transcranial magnetic stimulation for generalised anxiety disorder: a pilot randomised, double-blind, sham-controlled trial”. The British Journal of Psychiatry: The Journal of Mental Science3 (2016): 222-228.
  55. Boggio PS., et al. “Noninvasive brain stimulation with high-frequency and low-intensity repetitive transcranial magnetic stimulation treatment for posttraumatic stress disorder”. The Journal of Clinical Psychiatry8 (2010): 992-999.
  56. Narendran R., et al. “Improved working memory but no effect on striatal vesicular monoamine transporter type 2 after omega-3 polyunsaturated fatty acid supplementation”. PLoS One10 (2012): e46832.
  57. Kjaer TW., et al. “Increased dopamine tone during meditation-induced change of consciousness”. Brain Research Cognitive Brain Research 2 (2002): 255-259.
  58. Zeine F. “Awareness integration therapy: Clear the past, create a new future, and live a fulfilled life now”. Cambridge Scholars (2021).
  59. Zeine F. “Awareness integration: a new therapeutic model”. International Journal of Emergency Mental Health 2 (2014): 278-283.
  60. Jafari NZF EM. “Intentional Parenting”. Cambridge Scholars Publishing 1st edition (2022).
  61. Gerra ML., et al. “Early parent-child interactions and substance use disorder: An attachment perspective on a biopsychosocial entanglement”. Neuroscience and Biobehavioral Reviews 131 (2021): 560-580.
  62. McLaughlin T., et al. “Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: role of enhanced brain reward functional connectivity and homeostasis redeeming joy”. Journal of Behavioral Addictions 2 (2015): 106-115.
  63. McLaughlin T., et al. “Using the Neuroadaptagen KB200z™ to Ameliorate Terrifying, Lucid Nightmares in RDS Patients: the Role of Enhanced, Brain-Reward, Functional Connectivity and Dopaminergic Homeostasis”. Journal of Reward Deficiency Syndrome 1 (2015): 24-35.
  64. Febo M., et al. “Enhanced functional connectivity and volume between cognitive and reward centers of naive rodent brain produced by pro-dopaminergic agent KB220Z”. PLoS One4 (2017): e0174774.
  65. Dackis CA., et al. “Single-dose bromocriptine reverses cocaine craving”. Psychiatry Research4 (1987): 261-264.
  66. Lawford BR., et al. “Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele”. Nature Medicine 4 (1995): 337-341.
  67. Rouillard C., et al. “Behavioral and biochemical evidence for a different effect of repeated administration of L-dopa and bromocriptine on denervated versus non-denervated striatal dopamine receptors”. Neuropharmacology11 (1987): 1601-1606.
  68. Thanos PK., et al. “D2R DNA transfer into the nucleus accumbens attenuates cocaine self-administration in rats”. Synapse (New York, NY)7 (2008): 481-486.
  69. Blum K., et al. “Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary”. Theoretical Biology and Medical Modelling 5 (2008): 24.
  70. Perfumi M and Mattioli L. “Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% salidroside Rhodiola rosea extract in mice”. Phytotherapy Research 21.1 (2007): 37-43.
  71. Dahlgren A., et al. “Do alcohol-dependent individuals with DRD2 A1 allele have an increased risk of relapse? A pilot study”. Alcohol and Alcoholism (Oxford, Oxfordshire)5 (2011): 509-513.
  72. Blum K., et al. “Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual”. Journal of Systems and Integrative Neuroscience 7 (2020): 10.
  73. Lu H and Stein EA. “Resting state functional connectivity: Its physiological basis and application in neuropharmacology”. Neuropharmacology 84 (2014): 79-89.
  74. Lu H., et al. “Abstinence from cocaine and sucrose self-administration reveals altered mesocorticolimbic circuit connectivity by resting state MRI”. Brain Connectivity7 (2014): 499-510.
  75. Moeller SJ., et al. “Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity”. Neuroscience and Biobehavioral Reviews 61 (2016): 35-52.
  76. Volkow ND and Morales M. “The Brain on Drugs: From Reward to Addiction”. Cell4 (2015): 712-725.
  77. Volkow ND., et al. “Stimulant-induced dopamine increases are markedly blunted in active cocaine abusers”. Molecular Psychiatry 9 (2014): 1037-1043.
  78. Nestler EJ. “Transgenerational Epigenetic Contributions to Stress Responses: Fact or Fiction?” PLoS Biology3 (2016): e1002426.
  79. Blum K., et al. “Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms”. Journal of Addiction Research and Therapy 5 (2012): 139.
  80. Miller DK., et al. “Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports”. Postgraduate Medicine 6 (2010): 188-213.
  81. Steinberg B., et al. “Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case”. Open Journal of Clinical and Medical Case Reports 11 (2016): 1121.
  82. Blum K., et al. “Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2”. Postgraduate Medicine 6 (2010): 214-226.
  83. Febo M., et al. “Dopamine homeostasis: brain functional connectivity in reward deficiency syndrome”. Frontiers in Bioscience (Landmark Edition)4 (2017): 669-691.
  84. Blum K., et al. “A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management". Psychology Research and Behavior Management 14 (2021): 2115-2134.
  85. Substance A., et al. “Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health”. Washington (DC): US Department of Health and Human Services (2016).
  86. McLellan AT., et al. “Preaddiction-A Missing Concept for Treating Substance Use Disorders”. JAMA Psychiatry8 (2022): 749-751.
  87. Glechner A., et al. “Effects of lifestyle changes on adults with prediabetes: A systematic review and meta-analysis”. Primary Care Diabetes 5 (2018): 393-408.
  88. Jonas DE., et al. “U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Screening for Prediabetes and Type 2 Diabetes Mellitus: An Evidence Review for the US Preventive Services Task Force”. Rockville (MD): Agency for Healthcare Research and Quality (US) (2021).
  89. Gladden RM., et al. “Changes in Opioid-Involved Overdose Deaths by Opioid Type and Presence of Benzodiazepines, Cocaine, and Methamphetamine - 25 States, July-December 2017 to January-June 2018”. MMWR Morbidity and Mortality Weekly Report34 (2019): 737-744.
  90. Blum K., et al. “Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS)”. Molecular Neurobiology 3 (2014): 765-796.
  91. Braverman ER., et al. “Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis"”. International Journal of Environmental Research and Public Health 9 (2022): 5480.
  92. Comings DE and Blum K. “Reward deficiency syndrome: genetic aspects of behavioral disorders”. Progress in Brain Research 126 (2000): 325-341.
  93. Blum K., et al. “Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)”. Journal of Systems and Integrative Neuroscience 2 (2020): 10.
  94. Blum K., et al. “Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD)”. Global Journal of Addiction and Rehabilitation Medicine2 (2017): 555556.
  95. Blum K., et al. “Global opioid epidemic: doomed to fail without genetically based precision addiction medicine (PAM(™)): Lessons learned from America”. Precision Medicine1 (2017): 17-22.
  96. Levey DF., et al. “Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions”. Nature Neuroscience7 (2021): 954-963.
  97. Kimbrel NA., et al. “A genome-wide association study of suicide attempts in the million veterans program identifies evidence of pan-ancestry and ancestry-specific risk loci”. Molecular Psychiatry 4 (2022): 2264-2272.
  98. Hatoum AS., et al. “Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders”. Nature Mental Health3 (2023): 210-223.
  99. Li CY., et al. “Meta-analysis and genome-wide interpretation of genetic susceptibility to drug addiction”. BMC Genomics 12 (2011): 508.
  100. Blum K., et al. “Statistical validation of risk alleles in genetic addiction risk severity (GARS) test: Early identification of risk for alcohol use disorder (AUD) in 74,566 case-control subjects”. Journal of Personalized Medicine 9 (2022): 1385.

Kenneth Blum., et al. “Genetic Addiction Risk Severity (GARS) Test in Addiction Medicine: Early Identification of Pre-Addiction Phenotype”. EC Neurology  16.11 (2024): 01-21.